Table 5.

The effect of late-life BP variables on incident all-cause dementia and Alzheimer’s disease from stratified analyses by FOXO3 rs2802292 genotypes

		All cause dementia		Alzheimer’s disease
Genotype	BP variable	HR (95% CI) 1	p	HR (95% CI)	p
TG/GG (n = 1259)	HTN1	0.86 (0.66–1.13)	0.29	0.73 (0.53–1.00)	0.048
HTN2	0.85 (0.67–1.08)	0.18	0.72 (0.55–0.95)	0.021
SBP ≥140	0.84 (0.66–1.08)	0.18	0.71 (0.53–0.95)	0.019
SBP ≥160	0.78 (0.61–1.00)	0.051	0.61 (0.45–0.83)	0.0017
DBP ≥90	0.78 (0.58–1.04)	0.085	0.59 (0.41–0.85)	0.0042
DBP ≥95	0.67 (0.45–1.00)	0.050	0.55 (0.34–0.90)	0.017
TT (n = 1429)	HTN1	1.15 (0.89–1.48)	0.28	1.09 (0.81–1.46)	0.56
HTN2	1.09 (0.88–1.36)	0.44	1.16 (0.90–1.51)	0.25
SBP ≥140	1.05 (0.84–1.31)	0.68	1.00 (0.77–1.30)	0.99
SBP ≥160	1.12 (0.88–1.42)	0.37	1.08 (0.81–1.44)	0.62
DBP ≥90	1.16 (0.88–1.52)	0.29	1.26 (0.92–1.72)	0.15
DBP ≥95	0.72 (0.46–1.13)	0.15	0.68 (0.39–1.18)	0.17

¹HR and 95% CI for effect of late-life BP variables on all– cause dementia and Alzheimer’s disease, estimated within each FOXO3 genotype separately from the multivariate Cox models adjusted for baseline variables: age, education (years), APOE ɛ4, CASI score, BMI, plasma glucose, smoking (pack– year), alcohol drinking (ounces/month), physical activity index, and prevalent diabetes, CHD, stroke, and depressive symptoms. HTN1, SBP/DBP ≥140/90 mmHg or the self-reported use of anti-hypertensive medications; HTN2, SBP/DBP ≥160/95 mmHg or the self-reported use of anti-hypertensive medications.